Research Topics
Genomes and Genes | Teresa R JohnsonSummaryAffiliation: GenVec Inc Country: USA Publications
| Collaborators
|
Detail Information
Publications
Respiratory syncytial virus glycoprotein G interacts with DC-SIGN and L-SIGN to activate ERK1 and ERK2Teresa R Johnson
Viral Pathogenesis Laboratorya and Structural Biology Section, b Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
J Virol 86:1339-47. 2012....- Pulmonary eosinophilia requires interleukin-5, eotaxin-1, and CD4+ T cells in mice immunized with respiratory syncytial virus G glycoproteinTeresa R Johnson
Vaccine Research Center, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD 20892 3017, USA
J Leukoc Biol 84:748-59. 2008..These findings have important implications for the evaluation of candidate RSV vaccines... - Characterization of respiratory syncytial virus M- and M2-specific CD4 T cells in a murine modelJie Liu
Vaccine Research Center, NIAID, National Institutes of Health, 40 Convent Dr, Bethesda, MD 20892 3017, USA
J Virol 83:4934-41. 2009..Characterization of epitope-specific CD4 T cells by novel fluorochrome-conjugated peptide-I-A(b) tetramers allows detailed analysis of their roles in RSV pathogenesis and immunity... - Respiratory syncytial virus (RSV) G glycoprotein is not necessary for vaccine-enhanced disease induced by immunization with formalin-inactivated RSVTeresa R Johnson
VRC, NIAID, NIH, Bldg 40 Room 2614, 40 Convent Dr, MSC 3017, Bethesda, MD 20892 3017, USA
J Virol 78:6024-32. 2004.... - Vbeta14(+) T cells mediate the vaccine-enhanced disease induced by immunization with respiratory syncytial virus (RSV) G glycoprotein but not with formalin-inactivated RSVTeresa R Johnson
Vaccine Research Center, NIAID, NIH, Bldg 40, Room 2614, 40 Convent Dr, MSC 3017, Bethesda, MD 20892 3017, USA
J Virol 78:8753-60. 2004.... - Epitope-specific regulatory CD4 T cells reduce virus-induced illness while preserving CD8 T-cell effector function at the site of infectionJie Liu
Vaccine Research Center, NIAID, National Institutes of Health, 40 Convent Dr, Bethesda, MD 20892 3017, USA
J Virol 84:10501-9. 2010..Achieving the optimal balance of regulatory and effector T-cell function is an important consideration for designing future vaccines... 
Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infectionTeresa R Johnson
Viral Pathogenesis Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, USA
Pediatr Infect Dis J 23:S46-57. 2004..Thus gene delivery by vector, by DNA or by live attenuated virus are attractive vaccine approaches...- TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severityTeresa R Johnson
Vaccine Research Center, Viral Pathogenesis Laboratory, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892 3017, USA
Vaccine 27:3045-52. 2009..Furthermore, these data underscore that amplification of anti-viral immune responses may result in immunopathology rather than immune-mediated protection... - Treatment with anti-LFA-1 delays the CD8+ cytotoxic-T-lymphocyte response and viral clearance in mice with primary respiratory syncytial virus infectionJohn A Rutigliano
Vaccine Research Center, National Institutes of Health, Bethesda, Maryland 20892, USA
J Virol 78:3014-23. 2004..These results may prove useful in the development of new therapies to combat RSV infection or other inflammatory diseases... - Modified vaccinia virus Ankara immunization protects against lethal challenge with recombinant vaccinia virus expressing murine interleukin-4Lewis H McCurdy
Vaccine Research Center/NIAID/NIH, 40 Convent Drive, MSC 3017, Building 40, Room 2502, Bethesda, MD 20892-3017, USA
J Virol 78:12471-9. 2004..These data support the continued development of MVA as an alternative candidate vaccine for smallpox... - IL-13 is sufficient for respiratory syncytial virus G glycoprotein-induced eosinophilia after respiratory syncytial virus challengeTeresa R Johnson
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive MSC 3017, Building 40, Bethesda, MD 20892, USA
J Immunol 170:2037-45. 2003.... - Primary human mDC1, mDC2, and pDC dendritic cells are differentially infected and activated by respiratory syncytial virusTeresa R Johnson
Viral Pathogenesis Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health Bethesda, Bethesda, Maryland, United States of America
PLoS ONE 6:e16458. 2011..Defining the influence of RSV on the function of selected DC subsets may improve the likelihood of achieving protective vaccine-induced immunity... - RhoA signaling is required for respiratory syncytial virus-induced syncytium formation and filamentous virion morphologyTara L Gower
Vaccine Research Center, Building 40, Room 2502, NIAID, NIH, 40 Convent Dr, MSC 3017, Bethesda, MD 20892-3017, USA
J Virol 79:5326-36. 2005..These data suggest that viral filamentous protuberances characteristic of RSV infection are associated with RhoA signaling, are important for filamentous virion morphology, and may play a role in initiating cell-to-cell fusion... - Respiratory syncytial virus and innate immunity: a complex interplay of exploitation and subversionTeresa R Johnson
Vaccine Research Center, NIAID, NIH, Building 40 Room 2614, 40 Convent Drive MSC3017, Bethesda, MD 20892, USA
Expert Rev Vaccines 5:371-80. 2006..This review will address the impact of these findings on respiratory syncytial virus research... - Respiratory syncytial virus immunobiology and pathogenesisBarney S Graham
Viral Pathogenesis Laboratory, National Institutes of Health, Bethesda, Maryland 20892-3017, USA
Virology 297:1-7. 2002